Astrazeneca Pharma India Ltd vs Biofil Chemicals Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8369 as of 06 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 86.4 on March 2021 to 121 on March 2025 . This represents a CAGR of 6.97% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 106.81 crore on March 2021 to ₹ 66.92 crore on March 2025 . This represents a CAGR of -8.93% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.93 crore as compare to the Sep '25 revenue of ₹ 13.6 crore. This represent the decline of -93.16% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.17 crore as compare to the Sep '25 ebitda of ₹ 0.18 crore. This represent the decline of -5.56% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of -35.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products.
Later on, the Company was converted into a Public Limited Company on 7 May '92.
The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.
It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations.
The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Biofil Chemicals & Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr while Market cap of Biofil Chemicals & Pharmaceuticals Ltd is 56 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd?

As of May 6, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8369.45. On the other hand, Biofil Chemicals & Pharmaceuticals Ltd stock price is INR ₹34.44.

How do dividend payouts of Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Biofil Chemicals & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.